Burn$ Funding Announces Partnership with Jurman Medical Association, Set to Facilitate National Expansion of the Company

Peter J. Burns III

Burn$ Funding will an official business development partner of Jurman Medical, the most comprehensive provider of medical certification classes in the country.

We want our local partners to have pre-existing relationships with local companies – both healthcare industry-related companies, and others that require medical certification.”

— Peter J. Burns III

LA JOLLA, CALIFORNIA, US, April 30, 2019 /EINPresswire.com/ — Burn$ Funding announced today that it has become an official business development partner of Jurman Medical, the most comprehensive provider of medical certification classes in the country. As such, Burn$ Funding will spearhead Jurman Medical’s national rollout from its home state of California.

The announcement demonstrates the growing capability of Burn$ Funding, which was founded by serial entrepreneur Peter J. Burns III with the mission of driving the growth of America’s small and medium-sized businesses. In recent months, Burn$ Funding has emerged as a disruptive threat to the status quo, announcing:

● a bridge funding mechanism, funded by institutions, that helps entrepreneurs improve and then leverage their personal credit to obtain much needed growth capital for business, and
● a partnership with an aggregator of shelf corporations, which are entities that are no longer being used because their assets have been sold, typically through acquisition. Such corporations are viable because they have exemplary credit records, which means the new owner of the corporation can easily secure lines of credit.

In its partnership with Jurman Medical, Burns will not only make the above two tools available to entrepreneurs that want to become a local partner in one of more than 100 different markets being targeted by Jurman Medical, but he will also leverage his prodigious network to identify such local partners. In addition, Burns is enlisting his own marketing partners, who like him have decades of experience in the field, to assist in the campaign of creating a national footprint for Jurman Medical that highlights it value proposition as well as assist the company in attracting the right local partners.

“Both of us prefer local partners with connections as opposed to deep pockets,” said Burns. “While Burn$ Funding will assist the local partners with funding and Jurman Medical will assist them with business development and marketing, we also want them to have pre-existing relationships with local companies – both healthcare industry-related companies, and others that require medical certification.”

Burns added that once awareness has been achieved, the overwhelming benefit of using Jurman Medical will become obvious.

“What makes us different is that we provide training for CPR, BLS, IE ACLS, PALS, and NRP in one class, cutting down on the time and expense it takes to be trained,” said Devin Jurman, CEO of Jurman Medical. “Where this helps businesses is that we can get their staff trained in multiple areas in one session and back on the clock substantially quicker than other providers. In fact, by combining all the above training sessions into a single course, Jurman Medical is able to deliver all of this training in a single day, lasting less than 6 hours.

“Since we have the license to train multiple disciplines, it allows us to position ourselves in the marketplace as a one stop shop. For example, we differ from the Red Cross in that they do not offer the advanced medical training available exclusively through the American Heart Association (AHA). We are authorized by the AHA to brand our own certifications for CPR, First Aid, and AED, saving the typical student around $10 per class.”

About Burn$ Funding
Burn$ Funding is a financial service aggregating company that secures attractive financing on behalf of individuals. It offers revolving primary credit lines, from 6 months to 5 years old, of up to $20,000; bridge loans, where consumers can pay down existing credit using a $150,000 (and growing) per week revolving bridge loan product to pay down credit card balances; and 5 to 10-year-old shelf corporations with 6 AU tradelines, 3 primary tradelines, 80 paydex score with D&B, private funding and more.

holt hackney
hackney publications
5126320854
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Boost Oxygen Appears in the Wall Street Journal, Newsweek and Forbes

Boost Oxygen logo with three (3) sizes

Boost Oxygen Has Three Sizes

Boost Oxygen Advocate Paul Lachance featured in a Wall Street Journal article

Paul Lachance Featured in the Wall Street Journal

Boost Oxygen helps mountaineers and hikers summit mountains at-altitude

Jana Trusts Boost All the Way to the Summit

Paul Lachance’s cancer battle and Spartan Race participation is the subject of the Wall Street Journal article.

To have learned about Paul Lachance’s story, only after Paul decided to contact us and share it, is what truly motivates us every day.”

— Rob Neuner, CEO / Co-Founder

MILFORD, CT, UNITED STATES, April 30, 2019 /EINPresswire.com/ — Boost Oxygen has been featured recently in some very notable and recognizable media publications. The Wall Street Journal, Newsweek and Forbes have each featured the product in different ways. Newsweek identified the product as a trustworthy source of 95% pure oxygen that can help with altitude acclimation for ski resort towns that are at-altitude. Forbes featured Boost as a Mother’s Day gift idea for the Mom who loves an outdoor adventure; then again for an adventure that takes you to cold weather climates.

The Wall Street Journal piece was truly unique; having learned of this article being written by the subject of that article, Paul Lachance. Paul is an inspirational individual who has implemented Boost Oxygen since 2016. He integrates Boost Oxygen into his training and performance for Spartan races – and it helped him get through a couple of cancer battles that have taken place since he first shared his story of implementing the product.

Boost Oxygen co-founder and Chief Executive Officer Rob Neuner says, “When we launched in 2007, our goal was to provide a product that truly helps the consumer who understands the use of it, and, to become the number one trusted brand. Back then, the consumer really didn’t have any options for acquiring non-prescription, 95% pure oxygen in the retail market.”

Mr. Neuner goes on to say, “To have learned about Paul Lachance’s story, only after Paul decided to contact us and share it, is what truly motivates us every day. It is the authentic and genuine experiential story that matters to us and resonates with the consumer; we have always been about true and organic growth.”

When asked, Paul Lachance recalls how he came to have a bottle of Boost Oxygen in-hand:
“Several years ago, I was chatting with a pilot friend at the gym about a high altitude hike I just completed and told him about my issues with breathing thin air. The next day he brought me an aviation products catalog and suggested that I try this thing called ‘Boost Oxygen’. With nothing to lose, I ordered several bottles and tried the product on my next hike. For me it was love at first try…I almost ran up the hill at an elevation of over 10,000’. Just to make sure I tried it on a second hike; with the same results. Being excited that I found a product that would help in my Spartan adventures, I dropped a line to Boost Oxygen to tell them of my success. Our continuing partnership is based on a simple fact – the product works! To this day I use it and promote its use at every Spartan Race and any other opportunity that comes up. Not only does it work at high altitudes it is a great addition to lower level endurance events where the 95% pure oxygen supports longer lasting and more strenuous workouts. It’s a big part of my continuing success in my advanced age competitions.”

Boost Oxygen has become the #1 trusted brand of non-prescription, lightweight and portable, 95% pure oxygen. With a patented mask design that features an easy one-hand trigger operation, Boost is the only brand that offers three (3) sizes in Natural and aromatherapy options of Peppermint, Menthol-Eucalyptus and Pink Grapefruit. Here in 2019, a newly launch product called THINK TANK infuses 95% pure oxygen with rosemary.

Boost Oxygen is very proud to be available at trusted and recognized nationwide and regional retailers, including: CVS Pharmacy, Academy Sports + Outdoors, Dick’s Sporting Goods, Big 5 Sporting Goods, Cabela’s, Sportsman’s Warehouse, Scheels All Sports, Olympia Sports, REI, Walmart, Safeway, City Market, Murdoch’s Ranch and Home Supply, Dunham’s Sporting Goods, and FYE (For Your Entertainment) in addition to hundreds of independently owned retailers; as well as pharmacies, hotels and resorts. The website features a Store Locator where you can easily find a retailer that is convenient to any location in the continental United States, Alaska and Hawaii.

Boost Oxygen also exports worldwide to official distributors in Canada, the United Kingdom, all of Europe (ships from Prague), South Africa, New Zealand / Australia, Singapore, Malaysia, Bulgaria, Ecuador, Peru and Chile; with more coming online soon.

About Boost Oxygen:
Boost Oxygen is the #1 trusted brand of portable, lightweight 95% pure oxygen. Based in Milford, Connecticut, Boost Oxygen is a made in the USA product, available at retailers nationwide and exported worldwide. For more information, images and studies about the benefits of oxygen, visit the website: www.BoostOxygen.com. On social media, consumers post about their experiences on Facebook (@BoostOxygenUSA), Twitter (@BoostO2) and Instagram (@boostoxygen).

Brian Hoek
Pinstripes Media, LLC
+1 301-787-3743
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Boost Oxygen – Company Story


Source: EIN Presswire

First Drug Discovered in a Fruit Fly Used in Cancer Patients

Drug developer Tosk, Inc.,

Innovative drug developer Tosk designs drug to eliminate painful, life-threateningl side effects of front-line cancer therapies

Our scientists have developed two proprietary drug discovery platforms that use fruit flies to identify new drugs to combat cancer and other diseases.”

— Brian Frenzel, CEO, Tosk, Inc.

MOUNTAIN VIEW, CALIFORNIA, UNITED STATES, April 30, 2019 /EINPresswire.com/ — Drug developer Tosk, Inc. announced today that its patented drug, TK-90, which prevents the adverse side effects of frontline cancer therapies, succeeded in human clinical studies involving 25 head-and-neck cancer patients. TK-90 is the first drug discovered through screening using the common fruit fly (Drosophila melanogaster) to be tested in patients. The drug prevents mucositis, a painful, dose limiting, side effect suffered by many cancer patients undergoing chemotherapy and radiation therapy.

“Fruit flies have played an important role in scientific research for generations,” said Brian Frenzel, Tosk’s CEO, pointing out that six Nobel prizes in medicine or physiology have been awarded to scientists based on their research using the fruit fly, the latest in 2017. “However,” he added, “Drosophila have not been widely used for drug discovery and development by the pharmaceutical industry. Tosk is an exception. Our scientists have developed two proprietary drug discovery platforms that use fruit flies to identify new drugs to combat cancer and other diseases.”

Tosk, like the Nobel prize winners, uses the fruit fly because it has surprising similarities to humans at the genetic and molecular levels. Adult fruit flies, for example, have body parts that mimic mammalian hearts, kidneys, digestive tracts, and lungs. Nearly 70 percent of human disease-related genes have analogs in the fruit fly. “Because the life cycle of a fruit fly is short, only 50 days from birth to death and only two weeks from birth to adulthood, drug discovery in flies can be done quickly and cost effectively,” Frenzel says. “Using non-mammals as a discovery tool may yield new drugs that could not have been found using other, more traditional methods.”
Tosk selected TK-90 out of tens of thousands of compounds using what the company calls the Side Effect Fly™. Tosk incubates test compounds with a toxic chemotherapeutic that would otherwise prevent eggs from hatching and developing. Compounds that increase survival and result in larvae or mature fruit flies are "hits." Hits are tested in cell culture models using human cancer cells to select "leads" that do not affect the cancer killing efficacy of the chemotherapy. Tosk’s researchers then move to traditional models to confirm safety, adverse effect prevention, and non-interference with the beneficial effects of the cancer therapy.
“Instead of picking a target and fitting compounds to match, as most pharmaceutical companies do, our scientists let the fruit fly tell us which compounds are safe and effective. We then work backward to identify the molecular target or targets through which the drug works, opening what we believe is an exciting new vista on the process of drug discovery.”

Tosk has innovated a second, perhaps even more important, drug discovery platform, which it calls the Genetically Modified Fly™. Tosk integrates a human disease gene into Drosophila and then tests compounds for their ability to block the activity of the disease gene. This model is designed to discover drugs for disease targets that have previously been considered “undruggable.”

In addition to TK-90, Tosk has three other new drugs in its pharmaceutical development pipeline. The most advanced is TK-39, which prevents the dose-limiting, permanent, and potentially fatal damage to the heart caused by doxorubicin and other widely used, frontline cancer therapies. Another side effect preventing drug is TK-88, which prevents permanent kidney damage caused by platinum-based drugs such as carboplatin and cisplatin. Both were discovered using the Side Effect Fly.
Tosk’s “cancer moonshot” program addresses a top priority for the U.S. National Cancer Institute (NCI), developing a drug to block the activity of the human kRAS cancer gene. Funded by a $2 million grant from NCI, Tosk has used its Genetically Modified Fly for this purpose. The mutant kRAS gene drives as many as 30 percent of all cancers, including 90 percent of pancreatic, 45 percent of colon, and 35 percent of lung cancers.

Tosk’s fruit fly based drug screening technologies afford a new method to find small molecule, inexpensive drugs for difficult targets. “We think our fly models give us an advantage, a way to succeed where others have failed,” Frenzel says. Tosk’s first drug candidate, TK-90, has confirmed this in human clinical studies. Tosk believes that this is just the beginning, and plans to deliver many more drugs to improve outcomes for cancer patients.

Tosk, Inc. is a privately held biopharmaceutical company that develops new drugs to prevent the adverse side effects of existing, widely-used cancer therapies and to block the activity of cancer genes. For further information on the company, see www.tosk.com.

Brian Frenzel
Tosk, Inc.
+1 408-245-6838
email us here


Source: EIN Presswire

WiCis TeleHealth and continuous SpO2 from the Top of the World

Data Streamed Live from Mount Everest

Continuous SPO2. Safety in adventure has seen a game-changer with this technology

It's very cold

Base Camp in the evening.

Buddhist Prayer Flags on Base Camp

Buddhist Prayer Flags on Base Camp

WiCis connects climbers in near-real-time to rescue teams and loved ones to provide Telemedicine without limits.

Our goal is keeping our expedition safe & extending the reach and effectiveness of #tememedicine with #continouosSPO2 and #istreme. @Faexploring, @WiCisHealth. Monitor, Share, Protect.”

— Lukas Furtenbach, CEO. Furtenbach Adventures

LAKE TAHOE, NV, UNITED STATES, April 30, 2019 /EINPresswire.com/ — As climbers head to the top of the world on Mount Everest, WiCis is keeping them safer and extending the reach and effectiveness of TeleHealth. The company is once again proving their wearable technology platform that is continuously monitoring and sharing a climbers' vital signs and location with medical teams, rescue personnel and loved ones within seconds of being collected. May is summit month for Everest, and the challenge this year is to achieve the summit with the highest success rate while never compromising the safety of the climbers. With high oxygen flows and the most modern monitoring methods coming direct from critical care medicine, Furtenbach Adventures and WiCis seek to ensure base-camp oxygen saturations throughout the entire climb, thus never reaching the triggers that cause HAPE (High Altitude Pulmonary Edema) and HACE (High Altitude Cerebral edema) while on the mountain.

As part of the boundary-expanding expedition #EverestFlash19, which will culminate in a summit attempt on Mount Everest North in just 3 weeks, expedition leader Lukas Furtenbach of Furtenbach Adventures will be wearing a Nonin pulse oximeter with bluetooth-enabled and a Polar heart rate monitor that are continuously tracking heart rate, blood oxygen saturation, skin temperature, geo-location, altitude, speed and bearing as he climbs the world's highest peak. The climber's data is being transmitted in real-time via satellite to WiCis I-Streme Internet platform using a Thuraya Sat Sleeve, that is then analyzed their team medical doctor, Leo Montejo at Base Camp, Advanced Base Camp and the North Col. The heart of the WiCis solution is its web server app called WiCis CareFlows. A fast and modern TeleHealth solution that uses Microsoft Azure web servers. The WiCis TeleHealth solution combines: Forms, Videoconferencing and Vital Signs, all in a single Screen with a configurable Solution that is 100% Cloud-Based and hosted on Microsoft Azure, and designed for XXIst century medicine.

In addition to the continuous stream of biometric and geo-location information, of high-altitude mountaineering the climbers will be sharing updates and perspectives – and amazing views of the Himalayas on social media.

Links to both the live data stream and images will be shared on Twitter: http://twitter.com/wicissports and on Facebook: https://www.facebook.com/wicissports

Monitor, Share, Protect

As a key feature of the wearable platform, WiCis is combining and analyzing biometric data to provide ongoing snapshots of the climbers' overall health status. Serious – and even fatal – medical conditions such as edema, hypothermia and cardiac arrest can occur at high altitudes if climbers push themselves too hard and too far in the ultra-thin air. By continuously monitoring climbers for trends that may indicate they are at risk of developing these conditions, medical teams located in the US can intervene before a crisis emerges. Should an unforeseen medical or other emergency arise, rescue teams will have immediate access to the data needed to assess the climbers’ conditions and their exact location to ensure more rapid and more targeted medical care.

As a further measure of protection for the climbers, OCENS is providing continuous pinpoint weather data and forecasts. This information is displayed in real time on the WiCis dashboard and also on the WiCis Android App, which the climbers are using during the trek to stay in touch.

Proving the Limits to Expand the Reach of TeleHealth

WiCis is proving real-time remote biometric monitoring in the farthest reaches of the planet and under the harshest of conditions in order to expand the reliability and range of telemedicine solutions.

About WiCis: http://wicis.com/ and https://wicishealth.com/

Founded in 2011 by Harvard and Stanford anesthesiologist Dr. Leo Montejo (also founder of Picis), and in the Lake Tahoe area, the company’s goal is to promote the use of mHealth and tracking devices to make adventure sports, the military, and rescue teams to make their missions safer and engage with their followers with real time data that is either private or also available to social media platforms.

About Dr Leo Montejo

Dr. Leo Montejo has been designated the expedition doctor for Everest using the WiCis-Sports solution as a virtual health platform. He did his residency at Harvard in anesthesiology and critical care medicine, has been a Professor at Stanford in this specialty, and is an extreme sports enthusiast. Dr. Montejo has participated in four Himalayan expeditions, where he used the WiCIs I-Streme solution to stream his vitals, and share location and data with his team and family.

About Furtenbach Adventures: www.furtenbachadventures.com

Furtenbach Adventures is the most innovative organizer of tailor-made heliski-trips, expeditions and exclusive adventure travel. Personally tailored to our customers, for the highest demands, with the latest safety standards and best possible chances of success. Time is a valuable commodity. By climbing Mount Everest in just 4 weeks we are fundamentally changing the way high-mountaineering expeditions are run. While a regular Everest expedition can take almost two months, our Everest Flash expedition takes only 4 weeks – with increased safety and chance of success. In addition to the pre-acclimatization, maximum support is granted during the ascent, as well as the latest Telemedicine equipment, expert guides, experienced sherpas. Our goal is keeping our expedition safe & extending the reach and effectiveness of #Telemedicine with #continouosSPO2 and #istreme. Follow us to learn more about a new approach of uncompromised safety in high altitude mountaineering.

About Lukas Furtenbach:

Lukas Furtenbach is a father, geographer, alpinist, tourism consultant, professional hunter, private concierge, adventurer, cliff skier, mountaineer, organizer, operator and leader of adventure travel and expeditions to eight-thousander, a creative problem solver, out-of-the-box thinker, perfectionist and founder of Furtenbach Adventures.

WiCis
WiCis Health
+1 510-289-2929
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Geo-location Data Streamed Live. Monitor, Share, Protect. How an elite climbing team is heading to Everest using the most modern technology.


Source: EIN Presswire

Reliabilityweb.com Invites Nominations for the Annual Uptime Awards

Uptime Awards recognize achievements in reliability and asset management

Do you have an extraordinary reliability program? Nominate your program for the Uptime Awards

The International Maintenance Conference (IMC), December 9-12, 2019

The International Maintenance Conference (IMC), December 9-12, 2019

Uptime Awards Recognize Achievements in Reliability and Asset Management

FORT MYERS, FL, US, April 30, 2019 /EINPresswire.com/ — Reliabilityweb.com® is inviting nominations for the annual Uptime® Awards for accomplishments in reliability and asset management.

Does your organization have an extraordinary reliability program? Reliabilityweb.com invites nominations for the annual Uptime Awards, recognizing achievements in areas including Best Reliability Program, Best Asset Management Program, Best Work Execution Management Program, Best Leadership for Reliability Program, Best Asset Condition Management Program, and Best Reliability Engineering for Maintenance Program. In addition, there are awards for the Best Green Reliability Program, Special Recognition for Innovation in fields such as drone usage or the Internet of Things, and the Best Overall Program.

Participating in the Uptime Awards evaluation process brings many benefits. Organizations report that the process can help create an opportunity for external assessment and comparison, improve external communication and program detail reporting, and define the business cases for a sustainable program. It fosters teamwork and builds acknowledgement of all stakeholder contributions, generates internal recognition and program validation, and allows organizations to contribute to an emerging body of knowledge for effective asset management and maintenance reliability best practices. Sharing program details and best practices with the global maintenance reliability community also creates opportunities for external knowledge sharing and benchmarking relationships.

Past winners of the Uptime Awards include Southern Gardens Citrus, Jacobs NASA, Mercedes-Benz U.S. International, Cintas, Bristol-Myers Squibb, Malaysia Airports, Nova Scotia Power, and CBRE.

The deadline for submission of entries is May 15, 2019. Initial interviews will take place in June; top nominees will be interviewed in July. Winners will be notified on August 31, 2019. The Uptime Awards judging panel includes Terrence O’Hanlon, CEO and Publisher, Reliabilityweb.com and Uptime Magazine, Dave Reiber, Senior Reliability Leader, Reliabilityweb.com, and Jeff Smith, Senior Reliability Leader, Reliabilityweb.com.

Winners will be invited to participate in the Uptime Awards Ceremony, held at the International Maintenance Conference (IMC), December 9-12, 2019, on Marco Island, Florida. Winners will also receive a 45-minute presentation of their program at IMC, as well as an article in Uptime Magazine featuring their program.

For more information, or to submit a nomination, please visit www.uptimeawards.com.

About Reliabilityweb.com
Since 1999, Reliabilityweb.com discovers and delivers information on approaches that make the people we serve safer and more successful based on three lines of business:

Publishing: Digital and print including Uptime® magazine, Reliabilityweb.com Publishing with over 150 book titles, Reliabilityweb.com website in English and Spanish, and Reliability Radio®.

Conferences: The RELIABILITY Conference™, Maintenance 4.0 Digitalization Forum, The International Maintenance Conference, and MaximoWorld.

Training and Certification: Certified Reliability Leader® workshops and certification based on Uptime Elements – A Reliability Framework and Asset Management System; also Certified Maintenance Manager™ workshops and certification, developed by the Association of Asset Management Professionals (AMP).

For more information, please visit www.reliabilityweb.com.

Reliabilityweb.com®, Uptime®, The RELIABILITY Conference™, Certified Reliability Leader®, Reliability Radio® and Certified Maintenance Manager™ are the trademarks or registered trademarks of Reliabilityweb.com in the USA and in several other countries.

The trademarks, brand names, and company names listed are trademarks or registered trademarks of their respective owners or other third parties.

Terrence O'Hanlon CMRP CEO
Reliabilityweb.com
email us here
+1 239-333-2500


Source: EIN Presswire

Biopharma Process Systems & NIBSC to Lead Interactive Workshops for the Lyophilisation Conference 2019

SMi reports: There are two post-conference workshops taking place on the 5th June 2019, which will explain lyophilisation in its most simplistic terms.

LONDON, UNITED KINGDOM, April 30, 2019 /EINPresswire.com/ — SMi’s 7th annual Lyophilisation conference is returning to London, UK on the 3rd and 4th June 2019. There are two interactive workshops taking place on the 5th June, which gives delegates the opportunity to gain a greater understanding of Lyophilised Products, including analysis of physical properties and critical assessments.

Workshop A (5th June 08.30 – 12.30) is titled ‘From Physical Properties to Lyophilised Product’ led by Paul Matejtschuk, Principal Scientist & Section Head, Standardisation Science, NIBSC. Attendees can expect to learn details of the nature of the amorphous and crystalline state, how formulations influence the freeze drying of proteins and how you can, through analytical methodology (freeze drying microscopy, thermal analysis) arrive at a freeze drying cycle which should deliver a successful freeze dried end product.

Attendees of this workshop will gain basic training in fundamentals of freeze-drying formulation, gain experience of DoE approach to biologics formulation, and learn how to transfer knowledge from lab to pilot scale.

Workshop B (5th June 13.30 – 17.00) is titled ‘Critical Assessment of Lyophilised Products Using Analytical, Visual and Mechanistic Approaches’ led by Andrew Bright, Senior Scientist, Biopharma Process Systems. The workshop provides an overview of the critical quality attributes of lyophilised products and delves further into analytical, visual and mechanical methods typically used in industry. Using practical exercises and case studies, techniques will be explored to cover typical problem solving and how these can inform the overall freeze-drying process.

Attendees of this workshop will learn about the fundamentals of cake characterisation, obtain an understanding into the different approaches and their capabilities, gain practical insight and advice from experienced practitioners, and participate in the informal interactive nature of the structured sessions.

More information about the conference and workshops can be found on the event website at www.Lyophilisation-Europe.com/ein

Participating in this year’s conference provides a chance to connect with research and industry leaders and for those interested in attending, places can be reserved at www.Lyophilisation-Europe.com/ein

Lyophilisation 2019
Conference: 3rd-4th June
Workshops: 5th June
London, UK

For delegate enquiries contact Kieran Ronaldson on +44 (0) 20 7827 6744.

Organisations that wish to sponsor or exhibit at the conference can contact Alia Malick on +44 (0) 20 7827 6168

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Neill Howard
SMi Group Ltd
+44 20 7827 6000
email us here


Source: EIN Presswire

Abbott Laboratories to lead Panel Discussion with Eli Lilly & MedImmune at Pre-filled Syringes West Coast Conference

PFS PR7

LONDON, UNITED KINGDOM, April 30, 2019 /EINPresswire.com/ — Hear Edmond Israelski (Abbott Laboratories), Lin Li (Eli Lilly) and Diane Doughty (MedImmune) discuss improving patient centricity through digital health at the Prefilled Syringes West Coast Conference, taking place on June 3rd to June 4th in San Diego, USA.

Panel Discussion: Improving patient centricity through digital health – Day 2 | 11:15
Learning outcomes:
– Optimising user interface tools
– How to improve patient compliance
– Overcoming cyber security challenges
– The benefits of digital health and patient compliance

Moderator:
Edmond Israelski, Co-convenor of ISO and IEC Medical Devices Standards Committee, Abbot Laboratories

Panel Members:
Lin Li, Senior Consultant Engineer, Eli Lilly and Company Ltd
Diane Doughty, Senior Scientist, MedImmune

Further information is available at: www.prefilled-syringes-westcoast.com/einpr7

The Pre-Filled Syringes West Coast will gather a global audience of medical device experts and PFS industry leaders to discuss new developments and showcase the latest advancements, keeping you are the forefront of a booming industry.

The competitive PFS market has sparked great improvements as devices strive for higher quality, safety, and patient satisfaction. Pre-Filled Syringes West Coast is the perfect platform to strengthen knowledge in key principles such as human factors and patient centricity, connectivity and digital health, container closure integrity, the therapeutic opportunities of pre-filled, and manufacturing in the landscape of complex biologics, whilst honing in on emerging trends for parenteral devices.

The event brochure with the two-day agenda and speaker line-up is now available to download at www.prefilled-syringes-westcoast.com/einpr7

Book before April 30th to save $100.

Pre-filled Syringes – West Coast 2019
Date: June 3-4, 2019
Workshops: June 5, 2019
Location: Hyatt Regency Mission Bay, San Diego, California, USA
Website: www.prefilled-syringes-westcoast.com/einpr7

Pre-Filled Syringes West Coast 2019 Conference is proudly sponsored by:
Almac | Aptar | Credence MedSystems | Harro Hoefliger | Kaleidscope Innovation | Lonstroff Sumitomo Rubber North America | Mitsubishi Gas Chemical | Nemera | Plastic Ingenuity | PHC Corporation | Wilco | Zeon |ZebraSci | Zwick |

For all media inquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: hsidhu@smi-online.co.uk

For delegate enquiries contact Fateja Begum on +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu
SMi Group
+1 207-827-6088
email us here


Source: EIN Presswire

Clothing Store Inventory Software Market Global In 2019 – Epos Direct, Lightspeed Retail, NetSuite, Emperium POS, Vend

Clothing Store Inventory Software market across the globe is esteemed at a CAGR in between 2019 and 2024.

LONDON, LONDON, UK, April 30, 2019 /EINPresswire.com/ — The global Clothing Store Inventory Software market is esteemed at million Pounds in 2018 and is expected to achieve million Pounds before the end of 2024, growing at a CAGR in between 2019 and 2024.

The Asia-Pacific will involve for more market share in following years, particularly in China, also fast growing India and Southeast Asia regions.

North America, particularly The United States, will still play an important role which can't be overlooked. Any progressions from United States may influence the development trend of Clothing Store Inventory Software.

Europe now play a crucial role in the global market, by having a market size of xx million Pounds in the year 2019 and will be xx million Pounds in the year 2024, with a CAGR of xx%.

The primary research has been founded on detailed interviews and data gathered from discussions with leading industry specialists and option pioneers. The second study included several aspects such as research about on company websites, yearly reports, press releases, investor presentations, analyst’s presentations and a variety of global and national databases.

The report conveys Clothing Store Inventory Software market across diverse regions including the regions in India, Japan, South East Asia, Europe, China and USA. In this segment, chief attributes, for example, region wise Clothing Store Inventory Software production value and strategies, consumption, export/import details, growth rate from 2013 to 2018, market structure and status and SWOT analysis are included. Additionally, the research study classifies the Clothing Store Inventory Software Market based on major product types, application and end customers industries of Clothing Store Inventory Software. Furthermore, the report also covers topographical segregation for Clothing Store Inventory Software Market.

The Global Clothing Store Inventory Software Market has featured significant growth in recent past and will exhibit increased demand in the following forecasted years. The growing demand for Clothing Store Inventory Software industry is a key factor driving the market growth in the forecast period. The rapid usage is witnessing a big opportunity for the buyers, suppliers, and wholesalers in the Clothing Store Inventory Software market. In addition, the research study covers all the key attributes that have been impacting trend of the Clothing Store Inventory Software industry over the market growth.

The scope of the Report:

The Clothing Store Inventory Software industry is considered as a highly competitive, quickly changing, and significantly influenced by ongoing product developments and the market activities of other industry members.

This report examines the Clothing Store Inventory Software present market status and forecast outlook of Global and major regions, based on manufacturers, countries, product types and end industries. This report analyses the top players in global market and splits the Clothing Store Inventory Software market by product type and applications/end industries.

Top Key Players in Global Clothing Store Inventory Software market:

• Epos Direct
• Lightspeed Retail
• NetSuite
• Vend POS
• Revel Systems
• Springboard Retail
• COMCASH Retail ERP
• Amber POS
• Quetzal POS
• CORESense
• Agiliron
• RetailSTAR
• GiftLogic
• Celerant Technology
• NCR Counterpoint

Market Segment by Type, covers:

• Type I
• Type II

Market Segment by Applications can be divided into:

• Exclusive Shops
• Independent Shops
• Other

The Global Clothing Store Inventory Software Market 2018 is further emphasis based on product pricing, Clothing Store Inventory Software production volume, data pertaining to order and Clothing Store Inventory Software supply, and the revenue generated by the product. The report also offers upstream and downstream analysis covering major raw material used in manufacturing of Clothing Store Inventory Software along with detailed manufacturing sources. Diverse methodical, for example, investment returns, feasibility, SWOT analysis and market engaging analysis has been implemented in the research study to show comprehensive, detailed research study of the business for Clothing Store Inventory Software over the globe.

Simon Deluni
Epos Direct
+44 800 033 6888
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Cloud Pharmaceuticals to Present AI-Based Drug Design at Conferences in May

Cloud Pharmaceuticals is a leader in the design of new drugs using Artificial Intelligence

Don Van Dyke, COO Cloud Pharmaceuticals

COO Don Van Dyke to describe company technology and achievements in designing small molecule and peptide agents.

We are at the threshold of a revolution in medicine that will be more dramatic than any prior advance”

— Don Van Dyke

RESEARCH TRIANGLE PARK, NC, UNITED STATES, April 30, 2019 /EINPresswire.com/ — Don Van Dyke, COO of Cloud Pharmaceuticals Inc., an AI-based drug design company, is being featured as a speaker at several conferences in May. Van Dyke will discuss how Artificial Intelligence-based drug design is helping to transform the creation of new medicines.

During his sessions, Van Dyke describe Cloud Pharmaceuticals’ Quantum Molecular Design process, which enables faster progress at lower cost and a higher success rate than traditional methods, even with difficult targets. He will reference the company’s work with companies such as GSK to advance from target to lead molecule in months rather than years.

Schedule:

4th Drug Discovery Nexus Summit 2019 May 16-17, 2019, Boston, MA.

8th DRUG DISCOVERY INNOVATION PROGRAMME May 21, 2019
Boston, MA

PHARMA AI May 23 – 24, 2019 London, UK

“We are at the threshold of a revolution in medicine that will be more dramatic than any prior advance,” Van Dyke explains. “Designed drugs may be similar to discovered natural compounds, which will continue to give scientists clues about how nature and evolution have shaped biological interactions. But deeper understanding of the molecular basis for disease will bring about targeted attacks on the functioning of the very molecules that make us sick.”

Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new medicines. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications. For information visit www.cloudpharmaceuticals.com.

Irene Shipley
Cloud Pharmaceuticals
+1 984-329-2388
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

The Flu Shot – a few more good reasons to get one – new article by Pediatrician Dr. Kenneth Rebong

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Every year there seems to be the same discussion, whether or not to get a flu shot. Pediatrician Kenneth Rebong, MD, explains in a new published article.

Kenneth Pomar Rebong, MD (N/A:N/A)

While the CDC recommends that anyone older than 6 months get the flu shot, including pregnant women and people with chronic health conditions, there are exceptions”

— Dr. Kenneth P Rebong, pediatrician

SAN JOSE, CALIFORNIA, UNITED STATES, April 29, 2019 /EINPresswire.com/ — The flu shot discussion starts again every year when flu season starts. It is true that there are many different strains of the influenza virus and the vaccine might not necessarily protect you from getting the flu. However, the big picture is that if many get the flu shot, it will lower the overall rate flu infection. So, consider getting a flu shot not just for you, but for the people around you. Dr. Kenneth Rebong, MD, based in San Jose, California, provides his thoughts on this issue. The complete article is available on the Blog of Dr. Rebong at https://drkennethrebong.wordpress.com/

As usual, with all health issues, any questions or concerns should be discussed with your primary care doctor to make an informed decision. The flu shot is not for everybody, and it should be age appropriate. Your doctor can review your medical history and provide personalized advice. Also, the Centers for Disease Control and Prevention (CDC) maintain a website with detailed information about the flu shot, and related information. See https://www.cdc.gov/flu/protect/keyfacts.htm.

Our society generally tends to underestimate the seriousness of the flu and consider it similarly to the common cold. This is a common misconception. The Influenza virus is considerably more serious in nature. The CDC estimates that the flu has caused between 140,000 to 710,000 hospitalizations and as many as 12,000 and 56,000 deaths annually in the U.S. since 2010. Annual flu vaccine is the first step towards gaining protection against this disease and the CDC recommends it for everyone who is 6 months of age and older.

Consequences of the Flu

Typically, flu viruses start with infection to your nose, throat and lungs, but it can go on to cause a wide range of complications. While sinus and ear infections are moderate complications, Pneumonia is a serious flu complication that arises either due to the flu infection itself or if you’re simultaneously infected by bacteria as well as the flu virus.

Other more serious complications can include inflammation of the heart, brain or muscle or even multi-organ failure. An extreme inflammatory response can result in sepsis. In the past seven flu seasons, influenza vaccination prevented around 5.3 million illnesses and 85,000 hospitalizations and as per the CDC a mere 5% increase in the number of vaccinations could have further prevented as many as 483,000 influenza illnesses. It would have stopped another two hundred thousand plus influenza-associated medical visits, and around seven thousand influenza-associated hospitalizations across the U.S.A.

Some are more at risk than others

While anyone can get the flu, some people are at higher risk of a more severe form of infection. These include:
* Children younger than 5 years old, particularly those that are younger than 2 years old
* People older than 65 years old
* People suffering from asthma or chronic lung disease
* People with neurological conditions, heart disease and those suffering from blood, liver, kidney, endocrine and metabolic disorders
* People whose immune system has recently been compromised due to an illness
* Pregnant women

Does the flu shot really work?

Because there are different strains of the influenza virus each year, the flu vaccine is modified every year to target the particular strain that is predicted to circulate that year. However, there is no way of knowing which strain it might be. Thus, the effectiveness of the vaccine somewhat depends on how accurate the predictions are. Despite this, the CDC still strongly recommends that you get the flu vaccine as it still offers some degree of protection even if it’s not completely effective in preventing the disease. Because the influenza virus is transmittable, if a fewer number of people get sick, then the virus won’t be able to penetrate as deeply and spread. Besides CDC, other professional medical groups like the American Academy of Pediatrics, the National Foundation of Infectious Diseases and the American Medical Association also recommend an annual flu vaccine.

There are several options for the 2018-2019 flu season, these include:
* Standard dose flu shots given into the muscle. A needle is used to inject these, but for some people between the ages of 18 and 64 years old, a jet injector can be used.
* Shots made with adjuvant. These are suitable for older people.
* Shots made the help of virus previously grown via cell culture technique.
* Shots made using vaccine production technology. These do not employ the flu virus and follow a different mechanism.
* The nasal spray vaccine, also known as the live attenuated influenza vaccine (LAIV). This is recommended for use in non-pregnant individuals between the ages of 2 and 49 years. People with underlying medical conditions are advised against using the nasal spray flu vaccine.

What about side effects?

The influenza vaccine is formulated from an inactivated or weakened version of the influenza virus so you might experience flu-like symptoms post vaccination. These will subside however, and you won’t suffer from a full bout of the flu. There may also be some redness or swelling at the injection site, and low-grade fever. The side-effects are not really a concern because it just means that the vaccine is working and will be able to protect you from the actual virus.

The immunity from the previous year’s flu shot work will not be sufficient. First, the immune response generated by last year’s vaccine has gradually declined. Therefore, you need to be injected with a new one for continued protection. Also, as discussed above, the flu virus is constantly changing in strain. The flu vaccine is also analyzed accordingly and redesigned to combat new forms of the virus each year.

Too busy to get a flu shot?

Flu vaccines are easily available at many different locations such as doctor’s offices, clinics, pharmacies and college health centers. Many employers and schools offer them as well. It is recommended to get a flu shot before the virus starts spreading in your community as it takes around 2 weeks for your body to build up a sufficient immunity. If you’re looking to get one, it is best not to wait around and get one as soon as possible to ensure maximum protection.

Is it right for everybody?

As mentioned earlier, when in doubt, discuss it with your primary care doctor. While the CDC recommends that anyone older than 6 months get the flu shot, including pregnant women and people with chronic health conditions, there are exceptions. You should avoid the flu shot if you’re severely allergic to the components in the flu shot. Also, if you have ever had the Guillan-Barré Syndrome (An immune disorder), then consult your doctor before getting a flu shot.

One of the components involved in the manufacturing of flu vaccines are eggs, but as per the CDC, even if you suffer from egg allergies, you can still get the flu shot. In case your allergies are serious and you are concerned side effects from vaccinations, please consult your doctor.

About Dr. Kenneth P. Rebong

Dr. Kenneth Pomar Rebong, MD, a medical doctor in San Jose, California, and specializes in Pediatrics and Adolescent Medicine. He completed his Pediatric Residency at Rutgers University in New Brunswick, New Jersey.

https://medicogazette.com/dr-kenneth-pomar-rebong
https://hippocratesguild.com/dr-kenneth-pomar-rebong
https://drkennethrebong.wordpress.com/
https://www.linkedin.com/in/kenneth-pomar-rebong-md-4484a938/

Kenneth Pomar Rebong, MD
Kenneth Pomar Rebong, MD
+ +1 408-729-3232
email us here
Visit us on social media:
LinkedIn

Mayo Clinic Minute: The facts about 3 flu vaccine myths


Source: EIN Presswire